CYTOKINETICS ($CYTK) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of -$1.36 per share, beating estimates of -$1.41 by $0.05. The company also reported revenue of $1,580,000, beating estimates of $1,226,723 by $353,277.
You can see Quiver Quantitative's $CYTK stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CYTOKINETICS Insider Trading Activity
CYTOKINETICS insiders have traded $CYTK stock on the open market 42 times in the past 6 months. Of those trades, 0 have been purchases and 42 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ROBERT I BLUM (President & CEO) has made 0 purchases and 10 sales selling 123,361 shares for an estimated $5,376,844.
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 8 sales selling 61,889 shares for an estimated $2,681,219.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 17 sales selling 52,008 shares for an estimated $2,461,822.
- WENDALL WIERENGA has made 0 purchases and 3 sales selling 21,484 shares for an estimated $842,368.
- JOHN T HENDERSON has made 0 purchases and 2 sales selling 4,970 shares for an estimated $213,073.
- ROBERT ARTHUR HARRINGTON has made 0 purchases and 2 sales selling 1,350 shares for an estimated $55,993.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CYTOKINETICS Hedge Fund Activity
We have seen 165 institutional investors add shares of CYTOKINETICS stock to their portfolio, and 178 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ removed 4,610,302 shares (-95.5%) from their portfolio in Q4 2024, for an estimated $216,868,606
- DEEP TRACK CAPITAL, LP added 1,870,094 shares (+296.9%) to their portfolio in Q4 2024, for an estimated $87,969,221
- PFM HEALTH SCIENCES, LP removed 1,757,192 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $82,658,311
- FMR LLC removed 1,299,568 shares (-10.7%) from their portfolio in Q4 2024, for an estimated $61,131,678
- CAPITAL INTERNATIONAL INVESTORS added 1,096,164 shares (+inf%) to their portfolio in Q4 2024, for an estimated $51,563,554
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,062,136 shares (+11.0%) to their portfolio in Q4 2024, for an estimated $49,962,877
- UBS GROUP AG added 888,440 shares (+283.3%) to their portfolio in Q4 2024, for an estimated $41,792,217
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CYTOKINETICS Analyst Ratings
Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 04/24/2025
- RBC Capital issued a "Outperform" rating on 12/18/2024
- H.C. Wainwright issued a "Buy" rating on 11/18/2024
To track analyst ratings and price targets for CYTOKINETICS, check out Quiver Quantitative's $CYTK forecast page.
CYTOKINETICS Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 2 analysts offer price targets for $CYTK in the last 6 months, with a median target of $61.0.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $55.0 on 04/24/2025
- An analyst from Morgan Stanley set a target price of $67.0 on 03/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
